Who should not take B7-33?
Documented caution flags for B7-33 include hypotension or unstable cardiovascular status and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for B7-33 is limited.
Documented caution flags for B7-33
- Hypotension or unstable cardiovascular status
- Pregnancy / nursing
- Anyone risk-averse to pre-clinical-only data
Reported side effects to weigh
- Limited human data
- Theoretical hypotensive effect
- Injection-site reaction
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-15.